Bharat Biotech International Ltd said it started clinical trials of the Tuberculosis vaccine MTBVAC on adults in India. This is the first vaccine against Tuberculosis derived from a human source by the Spanish bio-pharmaceutical company, Biofabri.

The trials are carried out by Bharat Biotech in close collaboration with Biofabri, the company said. After completing a dose escalation trial in HIV uninfected adults, a Phase2 study in HIV-infected adults has started in 2024 to determine whether MTBVAC is safe in this population. The companies hope that the new vaccine will be a milestone in global vaccinology and called it an example of public-private, national and international collaboration.